Brazil's MedTech market just experienced a seismic shift. ANVISA, the national regulatory agency, has rolled out its new comprehensive framework, RDC 751, fundamentally changing the rules for medical device registration and market access. This move aligns Brazil closer than ever with international standards like the EU MDR. In this episode, we break down what this massive overhaul means for manufacturers. We dissect the new risk classification system, the updated submission pathways, and the critical changes to technical dossier requirements, providing a clear roadmap for anyone looking to enter or stay in Latin America's largest healthcare market.

Imagine a MedTech scale-up from the United States with an innovative orthopedic implant. They viewed Brazil as a primary expansion target but were stuck. Their main pain point was the regulatory divergence. Their FDA and EU technical files required a complete, costly, and time-consuming overhaul for the old Brazilian system, creating a barrier of over 18 months of work before they could even submit. With the new RDC 751, the question now is: can their existing EU MDR dossier fast-track their entry, or are there hidden complexities in the new rules that could still derail their launch?

Key Takeaways:

* How do the new four risk classes under RDC 751 compare to the previous Brazilian system?

* What specific documents from my EU MDR technical file can be repurposed for a Brazilian submission?

* Is the simplified `notificação` pathway truly faster for Class I and II devices?

* What are the new labeling and IFU requirements that manufacturers often overlook?

* How has the definition of a "medical device family" changed for submissions?

* What are the new obligations for the Brazil Registration Holder (BRH) under RDC 751?

* Are there any new post-market surveillance requirements that come with this framework?

At Pure Global, we specialize in demystifying complex regulatory changes like Brazil's RDC 751. We offer end-to-end solutions, from developing a tailored regulatory strategy to compiling your technical dossier and acting as your local Brazil Registration Holder. Our unique blend of local expertise and advanced AI tools streamlines your path to market access in over 30 countries. Don't let regulatory hurdles block your growth in LATAM. Contact us today at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your success.

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA, RDC 989, which establishes a new fast-track approval pathway for AI-driven diagnostic software. This is a pivotal moment for the MedTech industry in Latin America, promising to accelerate innovation and market access.

However, this opportunity comes with significant new hurdles. The regulation introduces complex requirements for predetermined change control plans, mandates the use of local Brazilian patient data for algorithm validation, and enforces stricter cybersecurity protocols. We explore the strategic implications for foreign and domestic manufacturers aiming to capitalize on this new landscape.

A real-world example. a U.S.-based SaMD company has its AI-powered radiological tool approved by the FDA. They targeted Brazil for their next expansion, but ANVISA's new RDC 989 just made their existing clinical data insufficient. They now face the urgent challenge of conducting a local validation study to qualify for the fast-track process, a costly and time-consuming roadblock they didn't anticipate.

Key Takeaways:

1. What exactly is a Predetermined Change Control Plan (PCCP) and how do I create one for ANVISA?

2. Does my existing clinical data from US or EU studies meet the new requirements for Brazil?

3. What are the specific cybersecurity and data privacy mandates under RDC 989?

4. How can I initiate a local clinical validation study in Brazil efficiently?

5. What is the timeline for compliance for products already under review by ANVISA?

6. How does this new fast-track pathway change the overall cost and timeline for market entry?

7. Will this regulation give local Brazilian MedTech startups a competitive advantage?

Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, helping you navigate complex regulations like RDC 989 to ensure your products reach the market efficiently. To understand how we can help with your market access strategy in Brazil and beyond, contact us at [email protected] or visit https://pureglobal.com/.

Brazil's national regulatory agency, ANVISA, has unexpectedly accelerated the compliance deadlines for its Unique Device Identification (UDI) system, creating a significant new challenge for MedTech manufacturers. This sudden shift requires immediate action on labeling, data management, and submission strategies to avoid market disruption.

While this presents a major hurdle, it also offers a competitive advantage to agile companies that can quickly adapt. This episode of LATAM MedTech Insights explores the specific details of ANVISA's new mandate, the potential pitfalls, and the strategic opportunities that arise from this regulatory surprise.

**Case Study:**

Imagine your company has a portfolio of high-risk cardiovascular devices thriving in the Brazilian market. Your team has been methodically preparing for a 2027 UDI compliance deadline. Suddenly, last week's ANVISA announcement pulls that deadline forward, demanding full compliance in just 18 months. Now you face an urgent crisis: redesigning all packaging, gathering extensive new data points, and navigating a complex database submission, all while your competitors are facing the same race against time. A single misstep could mean losing your registration and handing the market to a more prepared rival.

**Key Takeaways:**

* What are the exact new UDI compliance deadlines for different device classes in Brazil?

* Why are the new data submission requirements more complex than just standard labeling?

* How can this regulatory shift completely disrupt your current product roadmap and budget?

* What are the immediate operational steps your company must take to avoid a market lockout?

* Could this move by ANVISA trigger similar accelerated timelines in other LATAM countries?

* Is your current local representative in Brazil equipped to handle this sudden change?

* How can you turn this compliance crisis into a strategic advantage over your competitors?

Struggling to make sense of new regulations in Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in markets like Brazil with advanced AI tools to streamline your global market access, from regulatory strategy to technical dossier submission. Don't navigate the complexities alone. Contact Pure Global at [email protected] or visit https://pureglobal.com/ to secure your market presence.

This week, we dissect a sudden and significant regulatory enforcement shift from Brazil's ANVISA. The agency has accelerated the implementation of its comprehensive UDI traceability system for high-risk medical devices, a key part of its 2026-2027 agenda to harmonize with global standards. This move is catching many international manufacturers off guard, creating immediate challenges for market access and post-market compliance.

We explore the concrete implications of this accelerated timeline, from rejected submissions due to data inconsistencies to new, stringent requirements for adverse event reporting. Consider a company that has spent years preparing its Class IV device for the Brazilian market. They believe their dossier is perfect, but their submission is rejected on day one. The reason is not a failure in the device's clinical data, but an administrative error in the UDI database submission, a new and complex requirement. This single misstep could delay their launch by over six months, costing millions in potential revenue.

**Key Takeaways:**

* What are the exact database requirements for the new UDI submissions under ANVISA's accelerated timeline?

* How does this UDI enforcement align with the broader EU MDR harmonization trend in Brazil?

* Which specific device classes are most at risk for submission delays right now?

* What are the new post-market surveillance reporting requirements involving UDI data?

* How can you validate your UDI data for ANVISA's system before making a formal submission?

* What are the most common mistakes manufacturers are making with the new UDI requirements?

* How should this change impact your budget and timeline for entering the Brazilian market?

Navigating unexpected regulatory hurdles like these is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging our local expertise in Brazil and over 30 other markets. From developing an updated regulatory strategy to managing complex database submissions and ensuring post-market compliance, we streamline your path to market. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market access.

Brazil's regulatory agency, ANVISA, is launching a major digital overhaul for 2026, promising to slash approval times and streamline market access for medical devices. This episode dives into the core of ANVISA's new agenda, from the 'AnvisAI' project aimed at modernizing submissions to new fast-track queues for lower-risk devices.

We explore how this digital transformation is creating unprecedented opportunities for MedTech innovators. For instance, a company with a cutting-edge AI diagnostic tool that once faced a multi-year waiting period now sees a viable path to market, evidenced by recent approvals of complex software. But this new speed comes with higher expectations, demanding alignment with stringent global standards.

Key Questions This Episode Will Address:

- How will ANVISA's 2026 digital agenda change your market entry strategy for Brazil?

- Is your current technical dossier prepared for the new, stricter compliance framework?

- What are the hidden risks of misclassifying your software under the new accelerated pathways?

- How can the recent approval of AI imaging software serve as a roadmap for your submission?

- Are you prepared to leverage these regulatory changes to get ahead of your competitors in LATAM's largest market?

- What specific steps must you take to adapt your Quality Management System for Brazil's new landscape?

At Pure Global, we provide end-to-end regulatory consulting to help MedTech and IVD companies navigate this evolving environment. We combine local expertise with advanced AI tools to streamline global market access. Let us be your local representative and strategic partner in over 30 markets. Contact us for a consultation at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the groundbreaking news from Brazil's ANVISA. A new fast-track approval pathway for AI-powered medical software has just been announced, promising to revolutionize market access in Latin America's largest market. This is the opportunity the industry has been waiting for, but it comes with a complex twist.

This newfound speed is coupled with a formidable set of new cybersecurity and data privacy mandates, tailor-made for Brazil. We explore the hidden hurdles within this new regulation that could trip up even the most prepared global MedTech firms, turning a golden opportunity into a costly and time-consuming dead end.

Here is a real-world scenario. Your company has developed a breakthrough AI diagnostic tool, and you are ready to conquer the Brazilian market. The new fast-track promises a swift approval, but your application is suddenly stalled. The reason? You overlooked an obscure new requirement for a Brazil-based Data Protection Officer, a critical detail buried deep in the new regulation. Now you face months of delays, unforeseen costs to restructure your local operations, and the constant threat of a competitor beating you to market.

Key Takeaways for This Episode:

- What are the specific device classifications that qualify for ANVISA's new SaMD fast-track?

- How do the new Brazilian data privacy rules for MedTech differ from GDPR and HIPAA?

- Is a local, Brazil-based Data Protection Officer now mandatory for all foreign SaMD manufacturers?

- What are the three biggest cybersecurity vulnerabilities ANVISA will be auditing for in new submissions?

- How can you leverage your existing technical dossier for this new, unique submission process?

- What are the new requirements for post-market algorithm performance monitoring?

- Could this new Brazilian framework become the regulatory blueprint for other LATAM countries?

Navigating these regulatory shifts is what we do best. Pure Global transforms complexity into a competitive advantage. With our on-the-ground experts in Brazil and advanced AI-powered data tools, we provide end-to-end solutions for market access, from initial strategy and technical dossier submission to acting as your official local representative. Don't let regulatory hurdles block your entry into LATAM's most dynamic market. To ensure your AI MedTech product successfully navigates the new ANVISA landscape, contact us at [email protected] or visit https://pureglobal.com/ for a strategic consultation.

In a move that sent shockwaves through the MedTech industry, Brazil's regulatory agency, ANVISA, launched a mandatory new digital submission platform for high-risk medical devices last week. This sudden shift away from traditional paper-based systems has left many manufacturers scrambling to adapt.

This episode of LATAM MedTech Insights unpacks the immediate fallout of this decision. We explore the technical hurdles, the hidden documentation requirements, and the strategic implications for companies aiming to enter or expand within Latin America's largest market.

We'll look at the case of a cardiovascular device company whose critical product launch was jeopardized overnight by the new digital mandate. Their story highlights the severe financial and strategic costs of being unprepared for abrupt regulatory changes in Brazil.

Key Questions Answered:

1. What are the three biggest technical mistakes companies make on the new ANVISA portal?

2. How does this digital shift affect submission timelines for Class III and IV devices?

3. Are there any unannounced changes to the technical dossier requirements?

4. How can you leverage this change to potentially speed up your approval process?

5. What does this move signal about ANVISA's long-term regulatory strategy?

6. Is your local distributor truly equipped to handle this level of regulatory complexity?

7. How will this impact foreign manufacturers compared to local Brazilian companies?

At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and using advanced AI tools to streamline technical submissions. Don't let regulatory surprises derail your market access strategy. Contact us for a consultation at [email protected] or learn more by visiting https://pureglobal.com/.

This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard.

We explore why existing FDA or CE Mark documentation is no longer enough for the Brazilian market. This episode breaks down the new rules and discusses how adapting to them can provide a significant competitive advantage in Latin America's largest and most lucrative MedTech market.

**Case Study:** A U.S. startup with a cutting-edge AI diagnostic tool was poised to launch in Brazil. Despite having their clinical data and technical file ready, their submission was abruptly halted. The reason? It lacked a detailed cybersecurity vulnerability report adapted to Brazil's specific data privacy laws (LGPD). This unexpected roadblock could delay their launch by over a year, creating an opening for local competitors to seize market share. Are you prepared for this new reality?

**Key Questions Answered:**

* What specific cybersecurity standards has ANVISA now mandated for all SaMD products?

* How does the new guidance re-classify your AI-powered medical software?

* Are your existing clinical validation studies sufficient for the new Brazilian requirements?

* What are the three most common documentation pitfalls for foreign firms under the new guidelines?

* Why is appointing a local Brazil Registration Holder now more critical than ever?

* How can you turn Brazil's tough new regulations into a strategic advantage?

At Pure Global, we specialize in demystifying complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities.

Ready to accelerate your entry into Brazil? Contact us at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we explore the significant shift in Latin America's medical device industry. The region is rapidly moving from being a net importer to a powerful hub for local MedTech manufacturing. We unpack the key drivers behind this acceleration, including supply chain strategy, cost benefits, and new government incentives in major markets like Brazil and Mexico.

We dive into the real-world challenges and opportunities this trend presents. We analyze the complex decision-making process for companies weighing the benefits of local production against the formidable regulatory hurdles set by agencies like ANVISA and COFEPRIS. It's a strategic gamble that could redefine market leadership in the region.

What you'll learn in this episode:

- Why are multinational MedTech companies suddenly prioritizing local manufacturing in Latin America?

- What are the hidden regulatory costs of setting up a production line in Brazil versus Mexico?

- How can a company leverage local manufacturing to gain a competitive advantage?

- What is the number one mistake companies make when aligning with ANVISA's manufacturing practices?

- Are local supplier networks in countries like Colombia and Costa Rica mature enough for complex devices?

- How does in-country production change the strategy for post-market surveillance?

- What specific government incentives are most attractive for new MedTech manufacturers in 2026?

Navigating the transition to local manufacturing requires deep, on-the-ground expertise. Pure Global offers end-to-end regulatory solutions for MedTech companies, combining local experts with advanced AI tools to streamline market access. Whether you're developing a regulatory strategy for a new plant or registering your locally produced device, we act as your local representative in over 30 markets, including Brazil, Mexico, and Colombia. Let us help you turn complex regulatory challenges into a competitive advantage. Contact us at [email protected] or visit https://pureglobal.com/.

Brazil's health agency, ANVISA, has just introduced a stringent new cybersecurity regulation for all connected medical devices. This sudden move, aimed at enhancing patient safety and data protection, presents immediate and complex challenges for manufacturers. It escalates compliance costs and extends timelines, demanding a new level of technical documentation that many were not prepared for.

This podcast episode breaks down what the new rules demand and explores the strategic implications for companies operating in Latin America's largest market. We analyze the specific requirements, the reasons behind this abrupt shift, and how it will reshape the competitive landscape for both local and international MedTech firms.

**Key Takeaways:**

* What are the three core technical requirements of ANVISA's new cybersecurity rule?

* How does this new mandate affect devices already on the Brazilian market versus new submissions?

* Why is this change happening now, and is it part of a larger LATAM regulatory trend?

* What are the biggest compliance blind spots for foreign manufacturers entering Brazil?

* Can proactive compliance with this new rule become a competitive advantage?

* How will this impact the device registration timeline and budget for 2026?

* What specific documentation, like a Software Bill of Materials, is now non-negotiable?

Is your MedTech device ready for Brazil's new cybersecurity landscape? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise with advanced AI to streamline your market access and ensure you stay ahead of critical changes like this. Don't let regulatory surprises derail your strategy. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.